Continuous Lornoxicam Infusion for Orthopaedic Surgery

• Status: Suspended
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Perioperative continuous infusion of lornoxicam would be an effective and safe regimen to reduce the patient controlled morphine consumption after orthopaedic surgery.

After ethical approval, 96 patients scheduled for elective orthopaedic fracture surgery under general anaesthesia were randomly allocated to receive placebo, 12-hourly iv lornoxicam 16 mg or lornoxicam 16 mg followed with continuous infusion of 1.3 mg/hr., for 48 hours after surgery (n=32 per group). Anaesthesia was induced with propofol, sufentanil and rocuronium, and was maintained with 0.5-1 minimum alveolar concentration sevoflurane, sufentanil and rocuronium. Postoperative patient controlled morphine analgesia was used. Changes in heart rate, mean blood pressure and sevoflurane minimum alveolar concentration, visual analogue pain scores, and cumulative patient controlled morphine consumptions and blood loss for 48 hours, platelet functions, bone non-union and the presence of adverse effects were recorded.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Anesthetics; Lornoxicam; Morphine; Piroxicam

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists physical class I to III

• Age from 18 to 55 years

• Closed non comminuted long bone fractures

• Elective orthopaedic fracture surgery

• General anaesthesia

Exclusion Criteria:

• Hypersensitivity to lornoxicam

• Gastrointestinal ulceration or bleeding

• Cardiac diseases

• Pulmonary diseases

• Hepatic diseases

• Renal diseases

• Clotting diseases

• Bleeding diseases

• Bronchial asthma

• Diabetes mellitus

• Peripheral arterial occlusive disease

• Morbid obesity

• Pregnancy

• Alcohol or drug abuse

• Receiving other NSAIDs a day before surgery